Astellas Announces DAX-044 Option and License Agreement

Astellas Pharma announced an exclusive option and license agreement for DAX-044, according to The Pharma Letter. The asset is Audax Biosciences’ lead immuno-oncology Avikine candidate.

The announcement connects Astellas Pharma and Audax Biosciences around DAX-044 through an exclusive option and license arrangement. The Pharma Letter reported that Astellas announced the agreement.

Agreement focuses on DAX-044

DAX-044 is the candidate named in the exclusive option and license agreement. The Pharma Letter identifies it as Audax Biosciences’ lead immuno-oncology Avikine candidate.

The supplied report describes the agreement as exclusive and identifies both companies in connection with the arrangement. It does not provide further agreement terms, financial details, or development information.

What the announcement establishes

The reported event establishes a partnership-related development involving a named immuno-oncology candidate. Astellas Pharma is the company that announced the exclusive option and license agreement, while Audax Biosciences is identified with DAX-044.

• Astellas Pharma announced the agreement.
• The arrangement is an exclusive option and license agreement.
• DAX-044 is the asset covered by the announcement.
• The Pharma Letter describes DAX-044 as Audax Biosciences’ lead immuno-oncology Avikine candidate.

For pharmaceutical and biotech sales professionals, the announcement is a concise account-level update involving Astellas Pharma, Audax Biosciences, and an immuno-oncology asset. The supplied report centers on the agreement and the identification of DAX-044 as the lead Avikine candidate.

Publisher-reported context

The Pharma Letter reported the announcement as an exclusive option and license agreement for DAX-044. The report names no additional assets and provides no further terms in the supplied evidence.

The available information therefore remains focused on the companies, the agreement type, and DAX-044’s designation within Audax Biosciences’ immuno-oncology Avikine program.